Latuda Withdrawal & Tapering Guide
lurasidone
Boxed Warning
Increased mortality in elderly patients with dementia-related psychosis. Suicidality risk in young adults during initial treatment for depression.
In short
Latuda (lurasidone) is an Atypical Antipsychotic with a half-life of ~18 hours. Slow taper, with food (absorption issues at very low doses). Withdrawal symptoms, when they occur, usually begin 3-7 days after stopping and settle within 2-4 weeks.
- Class
- Atypical Antipsychotic
- Half-life
- ~18 hours
- Common doses
- 20mg, 40mg, 60mg, 80mg, 120mg tablets
- Withdrawal onset
- 3-7 days after stopping
- Typical resolution
- 2-4 weeks
Educational reference only. Dose changes are decided with the prescriber who knows your history.
Overview
Lurasidone is an atypical antipsychotic for schizophrenia and bipolar depression. Lower metabolic burden than olanzapine or quetiapine but akathisia is common. Must be taken with food (≥350 calories) for adequate absorption.
20mg, 40mg, 60mg, 80mg, 120mg tablets
Tablets: 20mg, 40mg, 60mg, 80mg, 120mg
Category B
Mechanism of Action
D2 antagonist; 5-HT2A antagonist; 5-HT7 antagonist; partial agonist at 5-HT1A. Lower H1 and muscarinic activity (less sedation, less anticholinergic burden).
Taper Notes
Slow taper, with food (absorption issues at very low doses). Watch for tardive symptoms unmasking on dose reduction.
Hyperbolic Tapering Guidance
Lurasidone has a more favorable metabolic profile than older atypicals, but the same tardive and discontinuation considerations apply.
Summary written by TaperCommunity, informed by the Maudsley Deprescribing Guidelines (Horowitz & Taylor) and related literature — see Sources & References below. Not affiliated with or endorsed by the Maudsley.
Withdrawal Timeline
3-7 days after stopping
1-2 weeks
2-4 weeks
Tardive dyskinesia symptoms can emerge or worsen weeks-to-months after taper — and are sometimes permanent
Common Withdrawal Symptoms
Interactions & Safety
Drug Interactions
- Strong CYP3A4 inhibitors (ketoconazole) — contraindicated
- Strong CYP3A4 inducers (rifampin) — contraindicated
- Grapefruit juice — increases exposure
Contraindications
- Strong CYP3A4 inhibitors or inducers
- Known hypersensitivity
Toxicity
Akathisia, somnolence, EPS, hyperprolactinemia, modest weight/metabolic changes (less than olanzapine/quetiapine), QT prolongation, neuroleptic malignant syndrome.
Pharmacokinetics
ADME Profile
Hepatic via CYP3A4 (major).
~99%
Need a clinician who understands tapering?
Browse our map of deprescribing-informed providers worldwide.
Other Drug Profiles
The arithmetic of a proportional reduction
The Maudsley Deprescribing Guidelines and NICE NG222 describe reducing Atypical Antipsychotic medications by a proportion of the previous dose rather than by a fixed amount, so each cut is smaller than the last. The table shows what that arithmetic produces at 10% per step, using 60 mg only as a worked example. How large each step is, how long it is held, and whether this pattern applies at all are decisions for the person and their prescriber.
| Step | % of starting dose | Worked example (60 mg start) |
|---|---|---|
| Start | 100% | 60 mg |
| Step 1 | 90% | 54 mg |
| Step 2 | 81% | 48.6 mg |
| Step 3 | 73% | 43.7 mg |
| Step 4 | 66% | 39.4 mg |
| Step 5 | 59% | 35.4 mg |
| Step 6 | 53% | 31.9 mg |
| Step 7 | 48% | 28.7 mg |
| Step 8 | 43% | 25.8 mg |
This is an illustration of a published method, not a schedule for anyone. It does not account for how long you have taken Latuda, your current dose, formulation, or history. TaperCommunity does not recommend doses or dose changes; those are agreed with your prescriber.
Frequently asked questions about Latuda
What are the withdrawal symptoms of Latuda (lurasidone)?
Common withdrawal symptoms of Latuda (lurasidone) include: rebound insomnia, rebound psychosis (in schizophrenia), anxiety, GI upset, tardive movements may unmask or worsen. Symptom severity varies by individual, dose, and duration of use.
How should I taper off Latuda (lurasidone)?
Slow taper, with food (absorption issues at very low doses). Watch for tardive symptoms unmasking on dose reduction. Lurasidone has a more favorable metabolic profile than older atypicals, but the same tardive and discontinuation considerations apply.
How long does Latuda withdrawal last?
Latuda withdrawal typically begins 3-7 days after stopping, peaks around 1-2 weeks, and resolves within 2-4 weeks. Tardive dyskinesia symptoms can emerge or worsen weeks-to-months after taper — and are sometimes permanent
Can I stop Latuda cold turkey?
Stopping Latuda abruptly is not recommended. Its half-life is ~18 hours, and the receptor adaptations built up during treatment do not reverse at that speed, so a sudden stop tends to produce the sharpest withdrawal. Prescribing guidance favours gradual, proportional reductions agreed with your prescriber.
How long does Latuda stay in your system?
Latuda (lurasidone) has a half-life of ~18 hours. A drug is mostly cleared after about five half-lives, so Latuda is largely out of the body about 4 days after the last dose, longer in older adults or with liver or kidney impairment. Withdrawal symptoms often begin before the drug has fully cleared and continue after it has, because the adaptations the brain made during treatment reverse more slowly than the drug leaves the blood.
Sources & References
Latuda (lurasidone) information on this page is sourced from peer-reviewed research, regulatory bodies, clinical guidelines, and patient-advocacy organizations.
Encyclopedic & chemical databases
Neutral, high-authority entity references.
Regulatory sources
Official prescribing information and safety notices.
Peer-reviewed research
Primary literature cited in this taper guide.
- Horowitz MA, Jauhar S, Natesan S, Murray RM, Taylor D 2021 — A method for tapering antipsychotic treatment that may minimize the risk of relapse (Schizophrenia Bulletin)
- Tranter R, Healy D 1998 — Antipsychotic withdrawal symptoms: phenomenology and pathophysiology (Journal of Psychopharmacology)
- Davies J, Read J 2019 — A systematic review into the incidence, severity and duration of antidepressant withdrawal effects (Addictive Behaviors)
Clinical guidelines
Evidence-based deprescribing and prescribing standards.
Deprescribing-specific resources
Clinician-facing references on tapering protocols.
- Royal College of Psychiatrists — Antipsychotics — UK clinical guidance on antipsychotic prescribing and discontinuation
- Council for Evidence-Based Psychiatry (CEP UK) — Evidence-based critique of long-term antipsychotic prescribing
- Deprescribing.org — Antipsychotic deprescribing algorithm for insomnia and BPSD
Patient-advocacy & lived-experience
Long-running communities documenting withdrawal experience.
- Surviving Antidepressants — antipsychotic tapering forum — Community archive of antipsychotic taper experiences
- Mad in America — antipsychotic archive — Independent journalism on antipsychotics and withdrawal
- Inner Compass Initiative — Withdrawal Project — Peer-led psychiatric drug withdrawal resources
- RxISK — adverse drug reaction reporting — Independent database of antipsychotic adverse-effect reports
TaperCommunity does not provide medical advice. Always consult a qualified prescriber before adjusting psychiatric medication.